Results 81 to 90 of about 1,268 (176)
Plenary Abstracts Session & Oral Presentations
HemaSphere, Volume 10, Issue S1, June 2026.
wiley +1 more source
Therapeutic Advances in Neurological DisordersMyasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis.
Zhouao Zhang +6 more
doaj +1 more source
Efgartigimod for treating generalised myasthenia gravis: a single technology appraisal [PDF]
This report is a critique of the company’s submission (CS) to NICE from argenx on the clinical effectiveness and cost effectiveness of efgartigimod (Vyvgart®) for treating generalised myasthenia gravis (gMG). It identifies the strengths and weaknesses of
Scott, David Alexander +5 more
core
BMC NeurologyBackground Guillain-Barré syndrome (GBS) is a peripheral neuropathy mediated by immunoglobulin G (IgG) autoantibodies, which can cause acute flaccid paralysis. Miller-Fisher syndrome (MFS) is a variant of GBS, and in some cases, MFS may overlap with GBS (
Bai Qi Hu +4 more
doaj +1 more source
Frontiers in NeurologyBackgroundAs targeted drug development in myasthenia gravis (MG) continues to advance, it is important to compare the efficacy of these drugs for better clinical decision-making. However, due to the varied regimens and dosages used in clinical trials for
Huahua Zhong +6 more
doaj +1 more source
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan
Neurology Clinical PracticeEfgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available in Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) and seronegative generalized MG.
Shigeaki Suzuki +18 more
openaire +2 more sources